Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Authors: Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: triple negative breast cancer, neoadjuvant treatment, residual tumors, adjuvant capecitabine, treatment discontinuation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1152123/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/9054ef5212d94639a5488c4656e59bc0

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.

Authors: Lucio, Tentori, Ilaria, Portarena, Marcella, Barbarino, Alessandra, Balduzzi, Lauretta, Levati, Matteo, Vergati, Annamaria, Biroccio, Barry, Gold, Luisa, Lombardi Maria, Grazia, Graziani

Source: Molecular Pharmacology; January 2003, Vol. 63 Issue: 1 p192-202, 11p